ADMA
ADMA Biologics Inc
9.50$
-1.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.7% | +6.6% | +7.3% | +3.8% | +25.1% | +4.5% | +9.4% | +1.8% | +9.8% | +6.6% | +2.9% | |
| – | -6.1% | +7.6% | +9.9% | +4.8% | +4.2% | +6.2% | +13.6% | +0.8% | +15.9% | +9.6% | +3.3% | |
| – | -30.8% | -11.7% | +94.7% | -1.7% | +19.0% | -30.6% | +26.1% | -32.0% | +42.8% | +57.7% | -1.5% | |
| – | -30.8% | -11.7% | +94.7% | -1.7% | +19.0% | -30.6% | +26.1% | -32.0% | +42.8% | +57.7% | -1.5% | |
| – | -12.4% | +81.0% | -39.3% | +66.5% | -0.3% | +98.8% | +10.4% | +25.5% | +15.1% | -14.2% | +1.7% | |
| – | +6.0% | +2.8% | +1.2% | -4.5% | -0.9% | +1.1% | +11.2% | +2.7% | +5.0% | +7.6% | +7.8% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +4.6% | -35.7% | +49.2% | +1.3% | -5.2% | -1.7% | +16.6% | -6.8% | +28.7% | -0.3% | -8.7% | |
| – | -1.8% | +1.6% | -4.6% | -15.6% | -12.0% | -1.8% | +16.7% | -14.1% | +6.9% | +87.1% | +0.4% | |
| – | +19.0% | +6.6% | -16.8% | +1.6% | +23.7% | -3.7% | +40.1% | -24.6% | +23.1% | +5.8% | +3.0% | |
| – | +6.3% | +4.6% | +4.5% | +4.5% | +2.1% | -2.5% | -5.1% | +223.2% | +7.3% | +14.0% | +10.6% | |
| – | +44.3% | +9.7% | -17.5% | +13.0% | +26.2% | +1.9% | +44.5% | -19.3% | -6.3% | -8.9% | +54.6% | |
| – | -8.0% | +0.2% | +0.2% | -22.7% | -28.6% | +0.3% | +1.2% | -4.5% | -1.1% | +179.2% | -0.4% | |
| – | -10.7% | +13.7% | +22.5% | +23.2% | +50.5% | +7.0% | +6.7% | +8.2% | +10.7% | -18.2% | +4.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -3.3% | +4.6% | +2.4% | +1.1% | +0.4% | -0.5% | +1.6% | -1.6% | -0.3% | -1.6% | -4.0% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.